|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 154.1 USD | +2.06% |
|
+2.69% | -3.66% |
| 03:25pm | Sector Update: Health Care Stocks Lean Lower Premarket Wednesday | MT |
| 01:27pm | Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex | MT |
Johnson & Johnson reported earnings results for the full year ended January 01, 2023. For the full year, the company reported sales was USD 94,943 million compared to USD 93,775 million a year ago. Net income was USD 17,941 million compared to USD 20,878 million a year ago.
Diluted earnings per share from continuing operations was USD 6.73 compared to USD 7.81 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.66% | 363B | |
| +61.53% | 848B | |
| +33.06% | 627B | |
| +15.06% | 318B | |
| +9.18% | 299B | |
| +13.64% | 243B | |
| +16.05% | 225B | |
| +15.67% | 179B | |
| +2.47% | 167B | |
| +1.49% | 125B |
JOHNSON & JOHNSON 
